| All presentations indicated with * were available for on demand viewing only until Wednesday, October 19, 2022
DAY 1 – Friday, October 14, 2022 |
| 10:00-10:10 |
Welcome Address by Anna Sureda, Spain, Mehdi Hamadani, USA, Stefano Luminari, Italy & Judith Trotman, Australia |
| 10:10-11:10 |
Session 1: Keynote Lectures
Chairs: Judith Trotman, Australia & Stefano Luminari, Italy |
| 10:10-10:15 |
Welcome by the chairs |
| 10:15-10:35 |
What is the new classification bringing to the lymphoma landscape?
Daphne de Jong, Netherlands |
| 10:35-10:55 |
How COVID impacts on risk-based selection of lymphoma care:
Sean Lim, UK |
| 10:55-11:10 |
Roundtable discussion
All speakers and chairs |
| 11:10-12:10 |
Session 2: Can we do better in risk stratification of lymphoma patients?
Chairs: Judith Trotman, Australia & Stefano Luminari, Italy |
| 11:10-11:15 |
Welcome by the chairs |
| 11:15-11:35 |
Radiomics in lymphoma: TMTV, Dmax and beyond:
Stephane Chauvie, Italy |
| 11:35-11:55 |
Liquid biopsy in lymphomas: From technical aspects to its clinical use:
Mark Roschewski, USA |
| 11:55-12:10 |
Roundtable discussion
All speakers and chairs |
| 12:10-14:10 |
Session 3: Hodgkin’s lymphoma
Chairs: Mehdi Hamadani, USA & Anna Sureda, Spain |
| 12:10-12:15 |
Welcome by the chairs |
| 12:15–12:45 |
Debate: Should BV-AVD be the new standard of care for advanced stage cHL? |
| 12:15–12:30 |
Yes: Andrea Gallamini, France |
| 12:30-12:45 |
No: Paul Bröckelmann, Germany |
| 12:45-13:15 |
Debate: Is radiotherapy still needed for early stage cHL? |
| 12:45-13:00 |
Yes: Carmen Martinez, Spain |
| 13:00-13:15 |
No: Wendy Osborne, UK |
| 13:15-13:45 |
Debate: Triple refractory cHL (auto-HCT / BV / CPIs) are candidates for … |
| 13:15-13:30 |
Allo-HCT: Carmello Carlo-Stella, Italy |
| 13:30-13:45 |
* CAR T-cells: Sairah Ahmed, USA |
| 13:45-14:10 |
Roundtable discussion
All speakers and chairs |
| 14:10-16:00 |
Session 4: Large B cell lymphomas: First-line therapy
Chairs: Mehdi Hamadani, USA & Nilanjan Ghosh, USA |
| 14:10-14:15 |
Welcome by the chairs |
| 14:15-14:45 |
Debate: Is Pola-R-CHP the new standard of care for DLBCL? |
| 14:15-14:30 |
Yes: Laurie Sehn, Canada |
| 14:30-14:45 |
No: Nilanjan Ghosh, USA |
| 14:45-15:15 |
Debate: Is R-DA-EPOCH the standard of care for double hit lymphomas? |
| 14:45-15:00 |
* Yes: Kieron Dunleavy, USA |
| 15:00-15:15 |
No: Narendranath Epperla, USA |
| 15:15-15:35 |
CNS prophylaxis in DLBCL – where are we now?
Matthew Wilson, UK |
| 15:35-16:00 |
Roundtable discussion
All speakers and chairs |
| 16:00-17:45 |
Session 5: Large B cell lymphomas: The relapse setting
Chairs: John Kuruvilla, Canada & Anna Sureda, Spain |
| 16:00-16:05 |
Welcome by the chairs |
| 16:05-16:25 |
Are improvements of salvage strategies in relapsed / refractory patients with DLBCL possible?
Christopher Fox, UK |
| 16:25-16:55 |
Debate: Is CAR T-cell therapy one-size-fits-all for primary refractory and early relapse patents with DLBCL? |
| 16:25-16:40 |
* Yes: Manali Kamdar, USA |
| 16:40-16:55 |
No: Alberto Mussetti, Spain |
| 16:55-17:25 |
Debate: Curing relapses after CAR T-cell therapy |
| 16:55-17:10 |
* With BiEsp: Michael Dickinson, Australia |
| 17:10-17:25 |
With Allo-HCT: Mazyar Shadman, USA |
| 17:25-17:45 |
Roundtable discussion
All speakers and chairs |
